Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some key facts match the label (fish-oil source; label notes uncertainty of risk in fish/shellfish allergy). However, most claims about shellfish allergy risk, clinician behavior/general practices, and comparative likelihood of safety are not supported by the provided prescribing information and include unsupported inferences.
Category Scores
Accurate Statements
Vascepa is made from purified omega-3 fatty acids, specifically eicosapentaenoic acid (EPA).
Section 5.2: VASCEPA contains ethyl esters of EPA.
Vascepa EPA is derived from fish oil.
Section 5.2: EPA obtained from the oil of fish.
Allergic reactions are possible with any medication or supplement.
Section 5.2: potential for allergic reactions in patients with known hypersensitivity is discussed (general existence of allergic reactions in context of hypersensitivity).
A shellfish allergy does not automatically predict a reaction to a fish-oil-derived drug.
Section 5.2: It is not known whether patients with allergies to fish and/or shellfish are at increased risk of an allergic reaction to VASCEPA.
The safest next step is to confirm the current Vascepa prescribing information allergen statements and excipients with a pharmacist.
No explicit label wording. However, Section 5.2 instructs to inform patients with known hypersensitivity and advise discontinuation and medical attention if reactions occur; consultation with labeling/pharmacist is not directly stated.
Unsupported Statements
Vascepa is not a shellfish ingredient.
The label excerpt provided does not state that Vascepa is not derived from shellfish or contains no shellfish ingredients; it only states the EPA is obtained from the oil of fish and that risk in fish/shellfish allergic patients is unknown (Section 5.2).
Patients with shellfish allergy often worry because many omega-3 supplements are sourced from fish, not shellfish.
Not supported by the provided label text.
For patient safety, it matters whether the allergy history involves fish versus shellfish.
The label states it is not known whether allergies to fish and/or shellfish increase risk, and advises informing patients with known hypersensitivity to fish and/or shellfish (Section 5.2). It does not provide a clear patient-safety rule distinguishing fish vs shellfish history.
The labeling of the exact product matters for patient safety.
Not supported by the provided label text.
For Vascepa, it is more relevant to consider fish allergy than shellfish allergy.
Label acknowledges hypersensitivity to fish and/or shellfish (Section 5.2) without ranking relevance.
If a patient has anaphylaxis or other severe allergy to fish, they should ask their clinician or pharmacist before using Vascepa.
Label advises informing patients with known hypersensitivity to fish and/or shellfish and to discontinue and seek medical attention if reactions occur (Section 5.2). It does not instruct patients to ask their clinician/pharmacist prior to use; contraindication is to known hypersensitivity to VASCEPA or its components (Section 4).
Clinicians generally check the patient’s exact allergen history (shellfish only versus shellfish plus fish).
Not supported by the provided label.
Clinicians generally check the product’s excipients and allergen statements on the package insert.
Not supported by the provided label.
Clinicians generally consider whether the patient has tolerated fish oil or omega-3 capsules in the past.
Not supported by the provided label.
If a patient has only shellfish allergy and has tolerated fish-derived foods or fish oil before, many clinicians consider Vascepa more likely to be safe than if the patient has had fish allergy.
Not supported by the provided label; label states the risk in fish/shellfish allergy patients is not known (Section 5.2).
The risk of allergic reactions is mainly driven by cross-reactivity, prior tolerance, and how the manufacturer controls sourcing and processing.
Not supported by the provided label.
If allergy concern is high (especially if the patient has reacted to fish oil before), clinicians may consider alternative lipid-lowering strategies.
Not supported by the provided label sections provided.
If allergy concern is high, clinicians may consider different omega-3 formulations depending on diagnosis and lab goals.
Not supported by the provided label sections provided.
Contradictions
Low
AI Statement
If a patient has anaphylaxis or other severe allergy to fish, they should ask their clinician or pharmacist before using Vascepa.
Label Reference
Section 4 (contraindication) and Section 5.2 (advice about informing/discontinuing if reactions occur).
Important Omissions
No label-accurate instruction that VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components (Section 4).
Importance:
Moderate
Missing label wording about advising patients with known hypersensitivity to fish and/or shellfish about potential allergic reactions to VASCEPA and to discontinue and seek medical attention if reactions occur (Section 5.2).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While some statements align with the label (fish-oil source; risk in fish/shellfish allergies is not known), several others add unsupported guidance about clinician decision-making and comparative safety by fish vs shellfish history without label support, and omit the explicit contraindication to hypersensitivity to VASCEPA/components and the label’s specific patient instruction (inform/discontinue and seek medical attention).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Most claims about shellfish vs fish allergy risk stratification and generalized clinician practices are not supported by the provided prescribing information; contraindication and specific label counseling language about hypersensitivity reactions/discontinuation are omitted.
Suggested Improvement
Restrict statements to label-supported facts: VASCEPA contains EPA obtained from fish oil (Section 5.2), it is not known whether fish/shellfish allergy increases risk (Section 5.2), advise patients with known hypersensitivity to fish and/or shellfish about potential allergic reactions and to discontinue and seek medical attention if reactions occur (Section 5.2), and include the contraindication for hypersensitivity to VASCEPA or its components (Section 4). Avoid asserting clinician generalizations or comparative safety based on fish vs shellfish allergy history unless explicitly stated in the label.